Rubedo Life Sciences

About:

Rubedo Life Sciences focuses on developing medicines that target the specific cells responsible for aging, known as pathologic cells.

Website: http://www.rubedolife.com

Twitter/X: liferubedo

Top Investors: Khosla Ventures, Refactor, Modi Ventures, Ahren Innovation Capital, Shanda Group

Description:

Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.

Total Funding Amount:

$53.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sunnyvale, California, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)rubedolife.com

Founders:

Julian Klein, Marco Quarta, Mark Gallop

Number of Employees:

11-50

Last Funding Date:

2024-04-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai